Status:
COMPLETED
Vessel Density in nAMD After Longterm Anti-VEGF Treatment Compared to Recently Started Anti-VEGF Treatment
Lead Sponsor:
Dr. med. Katja Hatz
Collaborating Sponsors:
Cenaug Foundation
Conditions:
Neovascular Age-related Macular Degeneration
Eligibility:
All Genders
Brief Summary
Neovascular age-related macular degeneration (nAMD) is characterized by the abnormal growth of blood vessels from the choroid into the subretinal space which leads to sub- and intraretinal fluid accum...
Detailed Description
Main outcome parameters are: * Vessel Perfusion Area (%) of central ETDRS subfields and peripapillar region as evaluated by OCTA (single measurement) * Blood flux index(\*) of central ETDRS subfields...
Eligibility Criteria
Inclusion
- To be eligible for participation, patients will be required to
- have been treated for sub- or juxtafoveal CNV due to nAMD with anti-VEGF intravitreal injections either for at least 20 times (longterm treatment eyes) or \<5 times (shortterm treatment eyes).
- give written consent to participation
Exclusion
- diagnosis of glaucoma/ocular hypertension at baseline of anti-VEGF treatment
- history of retinal vascular disorders like diabetic retinopathy, retinal vein/arterial occlusive disease, uveitis etc.
- history of papillary disease which might interfere with interpretation of peripapillary OCT/OCTA evaluation such as severe tilted disc, parapapillar CNV, papillar drusen, optic nerve neuritis, papillar edema etc.
- inability to perform OCTA examination of sufficient quality.
- history of any side effects of Tropicamide eye drops
Key Trial Info
Start Date :
January 7 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 30 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03833830
Start Date
January 7 2019
End Date
May 30 2019
Last Update
October 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vista Klinik
Binningen, Basel-Landschaft, Switzerland, 4102